Elbasvir and grazoprevir for the treatment of hepatitis C

References

• Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Henry L, Ong JP, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther. 2019;49(6):644–653.
   PubMed Web of Science ®Google Scholar
• Su T-H, Liu C-J, Tseng TC, et al. Hepatitis C viral infection increases the risk of lymphoid‐neoplasms: a population‐based cohort study. Hepatology. 2016;63(3):721–730.
   PubMed Web of Science ®Google Scholar
• Lee -J-J, Lin M-Y, Chang J-S, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PloS One. 2014;9(6):e100790.
   PubMed Web of Science ®Google Scholar
• Huang J-F, Dai C-Y, Hwang S-J, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102(6):1237.
   PubMed Web of Science ®Google Scholar
• Alazard-Dany N, Denolly S, Boson B, et al. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses. 2019;11(1):30.
   Web of Science ®Google Scholar
• Vermehren J, Park JS, Jacobson IM, et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–1187.
   PubMed Web of Science ®Google Scholar
• Yu M-L. Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol. 2017;32(8):1436–1442.
   PubMed Web of Science ®Google Scholar
• Papudesu C, Kottilil S, Bagchi S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int. 2016;11(2):152–160.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Negro F, Aghemo A, EASL. Recommendations on treatment of hepatitis C. final update of the series. J Hepatol. 2020;73(5):1170–1218.
   PubMed Web of Science ®Google Scholar
• zepatier_pi.pdf - z/zepatier/zepatier_pi.pdf. n.d.
   Google Scholar
• Tamori A, Enomoto M, Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators Inflamm. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Chatel-Chaix L, Baril M, Lamarre D. Hepatitis C virus NS3/4A protease inhibitors: a light at the end of the tunnel. Viruses. 2010;2(8):1752–1765.
   PubMed Web of Science ®Google Scholar
• Keating GM. Elbasvir/grazoprevir: first global approval. Drugs. 2016;76(5):617–624.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, de Kanter CTMM, van Hoek B. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39(7):589–611.
   PubMed Web of Science ®Google Scholar
• Sorbera MA, Friedman ML, Cope R. New and emerging evidence on the use of second-generation direct acting antivirals for the treatment of hepatitis C virus in renal impairment. J Pharm Pract. 2017;30(3):359–365.
   PubMedGoogle Scholar
• Maruyama A, Partovi N, Yoshida EM, et al. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transpl. 2017;32:35–41.
   PubMed Web of Science ®Google Scholar
• WW Y. Merck & Co., Inc., Whitehouse Station, NJ, USA; Celerion, Lincoln, NE, USA; Clinical Pharmacology of Miami, Miami, FL, USA; Orlando clinical research center, Orlando, FL, USA. Hepatology. 2014;60(suppl 1):1137A.
   Google Scholar
• Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis c virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Ch. 2012;56(8):4161–4167.
   PubMed Web of Science ®Google Scholar
• Xue W, Ban Y, Liu H, et al. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model. 2014 Feb 24; 54(2): 621-33.
   Google Scholar
• Lahser FC, Bystol K, Curry S, et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Ch. 2016;60(5):2954–2964.
   PubMed Web of Science ®Google Scholar
• Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8(12):1930–1940.
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20(11):2902–2912.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus coinfection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.
   PubMed Web of Science ®Google Scholar
• Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–572.
   PubMed Web of Science ®Google Scholar
• Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–36.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163(1):1–23.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Pearlman B, et al. efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–1086.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–e327.
   PubMed Web of Science ®Google Scholar
• Kawada N, Suzuki F, Karino Y, et al. Efficacy, safety and pharmacokinetics of grazoprevir (mk-5172) and elbasvir (MK-8742) in hepatitis C genotype 1 infected non-cirrhotic japanese patients (phase 2 portion in phase 2/3 combined study): 707. Hepatology. 2015;62(5):559A.
   Google Scholar
• Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: final results from the randomized C‐CORAL study. J Gastroenterol Hepatol. 2019;34(9):12–21.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane EJ, Peng C-Y, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164–175.e4.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Jacobson I, Rockstroh J, et al. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis. J Viral Hepatitis. 2019;26(3):329–336.
   PubMed Web of Science ®Google Scholar
• Abergel A, Christophe Hézode C, Asselah T. High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study. J Hepatol. 2018;68(SUPPLEMENT 1):S110.
   Web of Science ®Google Scholar
• Huang C-F, Hung C-H, Cheng P-N, et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE study): impact of baseline viral loads and NS5A resistance-associated substitutions. J Infect Dis. 2019;220(4):557–566.
   PubMed Web of Science ®Google Scholar
• Tsai T, Deng S, Hsu C. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan. J Med Virol. 2019;92(2):219–226.
   PubMed Web of Science ®Google Scholar
• Cheng P-N, Chen C-Y, Ming-Lung Y, et al. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: a real world multicenter observatory study in Taiwan. J Microbiol Immunol Infect. 2020:S1684–1182(20)30118–3. DOI:https://doi.org/10.1016/j.jmii.2020.05.004
   Google Scholar
• Puenpatom A, Cao Y, Yu X, et al. Effectiveness of elbasvir/grazoprevir in US veterans with chronic hepatitis C virus genotype 1b infection. Infect Dis Ther. 2020;9(2):355–365.
   PubMed Web of Science ®Google Scholar
• Hernández-Conde M, Fernández I, Perelló C, et al. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort. J Viral Hepat. 2018;26(1):55–64.
   PubMed Web of Science ®Google Scholar
• Foster GR, Agarwal K, Cramp ME, et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: a randomized trial. Hepatology. 2018;67(6):2113–2126.
   PubMed Web of Science ®Google Scholar
• Asselah T, Reesink H, Gerstoft J, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38(9):1583–1591.
   PubMed Web of Science ®Google Scholar
• Yu M-L, Chen P-J, Dai C-Y, et al. Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formosan Med Assoc. 2020;2020(119):1019–1040.
   Web of Science ®Google Scholar
• Zarębska‐Michaluk D, Jaroszewicz J, Buczyńska I, et al. Real‐world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. J Gastroenterol Hepatol. 2020;35(7):1238–1246.
   PubMed Web of Science ®Google Scholar
• Yu M-L, Chen P-J, Dai C-Y, et al. Taiwan consensus statement on the management of hepatitis C: part (II) special populations. J Formosan Med Assoc. 2020;119(7):1135–1157.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008;372(9635):321–332.
   PubMed Web of Science ®Google Scholar
• Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol. 2011;8(5):265–274.
   PubMed Web of Science ®Google Scholar
• Martinello M, Hajarizadeh B, Grebely J, et al. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol. 2018;15(7):412–424.
   PubMed Web of Science ®Google Scholar
• Boerekamps A, Weggheleire AD, van den Berk GE. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:(4):269–277.
   PubMed Web of Science ®Google Scholar
• Boyd A, Miailhes P, Chas J, et al. Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. J Antimicrob Chemoth. 2020;75(7):1961–1968.
   PubMed Web of Science ®Google Scholar
• Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet. 2019;394(10207):1451–1466.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Gutierrez JA, et al. Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a randomized trial. Hepatology. 2017;65(2):439–450.
   PubMed Web of Science ®Google Scholar
• de Lédinghen V, Laforest C, Hézode C. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of Patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study. Clin Infect Dis. 2017;66:1013–1018.
   Web of Science ®Google Scholar
• Lai T-S, Lee M-H, Yang H-I, et al. Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study. Hepatology. 2017;66(3):784–793.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Dixit V, et al. Meta‐analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepatitis. 2014;21(5):314–324.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Hsu J-W, Wei R, et al. Kidney function decline in patients with CKD and untreated hepatitis C infection. Clin J Am Soc Nephrol. 2018;13(10):1471–1478.
   PubMed Web of Science ®Google Scholar
• Lee -J-J, Lin M-Y, Yang Y-H, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56(1):23–31.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):364.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu H, Wu R, et al. Association of hepatitis C and B virus infection with CKD and impact of hepatitis C treatment on CKD. Sci Rep-uk. 2019;9(1):1910.
   PubMed Web of Science ®Google Scholar
• Caro L, Wenning L, Feng H-P, et al. pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019;75(5):665–675.
   PubMed Web of Science ®Google Scholar
• Atsukawa M, Tsubota A, Toyoda H, et al. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with Genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post hoc analysis of a multicenter study. J Gastroenterol Hepatol. 2019;34(2):364–369.
   PubMed Web of Science ®Google Scholar
• Liu C-H, Peng C-Y, Fang Y-J, et al. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. Sci Rep. 2020;10:405.
   PubMed Web of Science ®Google Scholar
• Choi DT, Puenpatom A, Yu X, et al. Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020;174:104698.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, Jansen AME, Ter Horst PGJ. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet. 2019;58(10):1237–1263.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Poordad F, Firpi-Morell R, et al. Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and child-pugh class B cirrhosis: the C-SALT study. Clin Transl Gastroenterol. 2019;10(4):e00007.
   PubMed Web of Science ®Google Scholar
• Pereira BJG, Milford EL, Kirkman RL, et al. Transmission of hepatitis C virus by organ transplantation. New Engl J Med. 1991;325(7):454–460.
   PubMed Web of Science ®Google Scholar
• Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. New Engl J Med. 2019;380(17):1606–1617.
   PubMed Web of Science ®Google Scholar
• Cypel M, Feld JJ, Galasso M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Respir Med. 2019;8(2):192–201.
   PubMed Web of Science ®Google Scholar
• Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C‐positive kidneys for hepatitis C‐positive recipients. Am J Transplant. 2010;10(5):1238–1246.
   PubMed Web of Science ®Google Scholar
• Mulvihill MS, Cox ML, Bishawi M, et al. Decline of increased risk donor offers on waitlist survival in heart transplantation. J Am Coll Cardiol. 2018;72(19):2408–2409.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. New Engl J Med. 2017;376(24):2394–2395.
   PubMed Web of Science ®Google Scholar
• Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C–infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273.
   PubMed Web of Science ®Google Scholar
• Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533.
   PubMed Web of Science ®Google Scholar
• McLean RC, Reese PP, Acker M, et al. Transplanting hepatitis C virus–infected hearts into uninfected recipients: a single‐arm trial. Am J Transplant. 2019;19(9):2533–2542.
   PubMed Web of Science ®Google Scholar
• Hsiao -H-H, Liu Y-C, Wang H-C. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Transpl Infect Dis. 2014;16(6):1003–1006.
   PubMed Web of Science ®Google Scholar
• Hsieh M-H, Tsai -J-J, Hsieh M-Y, et al. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. Plos One. 2014;9(4):e94791.
   PubMed Web of Science ®Google Scholar
• Re VL, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis c virus compared with hepatitis C virus–monoinfected patients. Ann Intern Med. 2014;160(6):369–379.
   PubMed Web of Science ®Google Scholar
• Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A US–Canadian multicenter study. J Hepatol. 2007;47(4):527–537.
   PubMed Web of Science ®Google Scholar
• Chen T-Y, Ding EL, Seage GR, et al. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49(10):1605–1615.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Li S-W, Ku S-Y, et al. Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV coinfection: a non-randomized, open-label clinical trial. Infect Drug Resist. 2019;12:937–945.
   PubMed Web of Science ®Google Scholar
• Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(1):S33–S45.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e1207.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Argiana V. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol. 2017;31:35–41.
   PubMed Web of Science ®Google Scholar
• Qvigstad C, Tait RC, Rauchensteiner S, et al. The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (Baltimore). 2018;97(39):e12551.
   PubMed Web of Science ®Google Scholar
• Eyster ME, Kong L, Li M, et al. Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol. 2016;91(9):E335–E340.
   PubMed Web of Science ®Google Scholar
• Hézode C, Colombo M, Bourlière M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66(3):736–745.
   PubMed Web of Science ®Google Scholar
• Fransen L, D’hondt P, Bielen R, et al. Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single‐centre experience. Haemophilia. 2019;25(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Liang P-C, Lin P-C, Huang C-I, et al. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc. 2018;117(1):14–23.
   PubMed Web of Science ®Google Scholar
• Brown A, Hézode C, Zuckerman E, et al. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C‐SCAPE study. J Viral Hepatitis. 2018;25(5):457–464.
   PubMed Web of Science ®Google Scholar
• Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016;65(6):1112–1119.
   PubMed Web of Science ®Google Scholar
• George J, Burnevich E, Sheen I, et al. Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatol Commun. 2018;2(5):595–606.
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017;52(4):520–533.
   PubMed Web of Science ®Google Scholar
• Nangia G, Vierling JM, Kwo P, et al. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials. J Viral Hepat. 2020;62:562A– 12.
   Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol. 2013;59(3):434–441.
   PubMed Web of Science ®Google Scholar
• Huang C-F, Yu M-L. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol. 2020;26(3):251–260.
   PubMed Web of Science ®Google Scholar
• Grassi G, Caprio GD, Fimia GM, et al. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol. 2016;22(6):1953–1965.
   PubMed Web of Science ®Google Scholar
• Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9(9):1089–1097.
   PubMed Web of Science ®Google Scholar
• Dai C, Yeh M, Huang C, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol. 2015;30(5):879–884.
   PubMed Web of Science ®Google Scholar
• Dai C-Y, Chuang W-L, Ho C-K, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49(1):9–16.
   PubMed Web of Science ®Google Scholar
• Batsaikhan B, Huang C-I, Yeh M-L, et al. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget. 2018;9(30):21313–21321.
   PubMedGoogle Scholar
• Huang C, Dai C, Yeh M, et al. Cure or curd: modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36(11):920–928.
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther. 2016;22(1):81–88.
   Web of Science ®Google Scholar
• Pedersen MR, Patel A, Backstedt D, et al. Genotype specific peripheral lipid profile changes with hepatitis C therapy. World J Gastroenterol. 2016;22(46):10226–10231.
   PubMed Web of Science ®Google Scholar
• Drazilova S, Gazda J, Janicko M, et al. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol. 2018;2018:1–11.
   Web of Science ®Google Scholar
• Ambrosino P, Lupoli R, Minno AD, et al. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: a systematic review and meta-analysis. Int J Cardiol. 2016;221:746–754.
   PubMed Web of Science ®Google Scholar
• Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150(145–155):e4.
   PubMed Web of Science ®Google Scholar
• Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67(3):553.
   PubMed Web of Science ®Google Scholar